

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Naloxegol for treating opioid-induced constipation

Batch 33

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

An issue raised by a consultee was that any recommendations specifying an upper age limit for receiving treatment with naloxegol may discriminate against elderly people. The manufacturer clarified that it was not expecting that the marketing authorisation would include an upper age limit. A consultee also raised that the Committee should be aware when making its preliminary recommendations that if these recommendations specify a required prior length of treatment with prior laxative treatment, this treatment period could have an impact on access to naloxegol treatment for people with cancer pain and opioid-induced constipation who may have a short life expectancy.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

It is not expected that the marketing authorisation would include an upper age limit for receiving treatment with naloxegol, and therefore it is not expected that this potential equality issue would need to be addressed by the Committee when making its preliminary recommendations.

The Committee should be aware when making its preliminary recommendations that if these recommendations specify a required prior length of treatment with prior laxative treatment, this treatment period could have an impact on access to naloxegol treatment for people with cancer pain and opioid-induced constipation who may have a short life expectancy.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No changes to the draft scope have been required to highlight potential equality issues.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No changes to the matrix have been required to highlight potential equality issues.

Approved by Associate Director (name): ... Janet Robertson

Date: 05 August 2014